SynthesisFrontiers in oncology2023
Human gut, breast, and oral microbiome in breast cancer: A systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.Annals of medicine · 2026Pooled it
- Gut microbiota and breast cancer: systematic review and meta-analysis.Breast cancer (Tokyo, Japan) · 2025Pooled it
- Changes in the fecal microbiota of breast cancer patients based on 16S rRNA gene sequencing: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.Gut microbes · 2026Review
- The emerging role of non-Gastroenterology report · 2026Review
- The dialogue between breast cancer and microorganisms.Frontiers in cellular and infection microbiology · 2026Review
- Host-microbiome interactions in breast cancer progression and treatment response.Frontiers in medicine · 2026Review
- Antibiotic use and survival from breast cancer: A population-based cohort study in England and Wales.Nature communications · 2025Article
- Metagenomic analyses reveal E. coli-derived siderophores as potential signatures for breast cancer.Journal of translational medicine · 2025Article
- Tumor-associated microbiota: Multi-cancer landscape, mechanistic insights and clinical translation (Review).Oncology letters · 2025Review
- Salivary BCAA, Glutamate, Glutamine and Urea as Potential Indicators of Nitrogen Metabolism Imbalance in Breast Cancer.Current issues in molecular biology · 2025Article
- Guardians in the Gut: Mechanistic Insights into a Hidden Ally Against Triple-Negative Breast Cancer.Cancers · 2025Review
- The microbiome in cancer.iMeta · 2025Review
- Article
- Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients.NPJ breast cancer · 2025Article
- Differences in the Gut Microbiota in Long-Term Infertile Holstein Repeat Breeder Cows and Healthy Fertile Holstein Cows.Animals : an open access journal from MDPI · 2025Article
- Microbial Signatures in Breast Cancer: Exploring New Potentials Across Body Niches.International journal of molecular sciences · 2025Review
- Exploring the Microbiome in Breast Cancer: The Role ofMicroorganisms · 2025Review
- The dark matter in cancer immunology: beyond the visible- unveiling multiomics pathways to breakthrough therapies.Journal of translational medicine · 2025Review
- Spatial Heterogeneity of Intratumoral Microbiota: A New Frontier in Cancer Immunotherapy Resistance.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dysbiosis characterises breast cancer through direct or indirect interference in a variety of biological pathways; therefore, specific microbial patterns and diversity may be a biomarker for the diagnosis and prognosis of breast cancer. However, there is still much to determine about the complex interplay of the gut microbiome and breast cancer. Objective: This study aims to evaluate microbial alteration in breast cancer patients compared with control subjects, to explore intestine microbial modification from a range of different breast cancer treatments, and to identify the impact of microbiome patterns on the same treatment-receiving breast cancer patients. Methods: A literature search was conducted using electronic databases such as PubMed, Embase, and the CENTRAL databases up to April 2021. The search was limited to adult women with breast cancer and the English language. The results were synthesised qualitatively and quantitatively using random-effects meta-analysis. Results: A total of 33 articles from 32 studies were included in the review, representing 19 case-control, eight cohorts, and five nonrandomised intervention researches. The gut and breast bacterial species were elevated in the cases of breast tumours, a significant increase in Conclusions: This systematic review elucidates the complex network of the microbiome, breast cancer, and therapeutic options, with the objective of providing a link for stronger research studies and towards personalised medicine to improve their quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.